Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation, simulation-enabled performance, intelligence solutions, and medical communications for the biopharma industry, has announced an optimization of its business unit and leadership structure. This strategic move, effective August 30, 2024, is aimed at supporting future growth in the wake of the Company’s recent acquisitions.
“Over the past year, we’ve made two pivotal acquisitions, including the largest in our history,” said Shawn O’Connor, CEO of Simulations Plus. “These moves have doubled our total addressable market, created a unique platform, and significantly strengthened our talent pool. As we integrate Pro-ficiency into our operations, we’ve identified synergies that allow us to reorganize our business units and leadership to better serve our clients and maximize growth. Our expanded team is focused on accelerating drug development and delivery to patients.”
“Integrating Pro-ficiency has led us to optimize our resources and create two new business units: Adaptive Learning & Insights and Medical Communications. Additionally, the Regulatory Strategies business unit will transition into a new Regulatory Strategies Center of Excellence. This reorganization will enhance our visibility and cross-selling opportunities within the sales organization, driven by the rising demand for biosimulation solutions,” O’Connor added.
“Our comprehensive and innovative offerings now cover the entire drug development continuum, positioning Simulations Plus uniquely to drive growth and profitability. We are excited about the potential to create long-term value for all stakeholders.”
Simulations Plus also announced key leadership promotions:
- Steven Chang is promoted to President, Quantitative Systems Pharmacology. Chang, who joined with the acquisition of Immunetrics, has over 30 years of experience in technology entrepreneurship and market needs identification.
- Jenna Rouse is promoted to President of Adaptive Learning & Insights. Rouse, formerly Chief Markets Officer, Clinical at Pro-ficiency, has extensive experience in simulation-enabled training and professional development in clinical trials.
- Murry Alper is promoted to President of Medical Communications. Alper, who joined with Pro-ficiency, has nearly 30 years of life sciences experience and a track record of founding and leading medical communications agencies.
- Sandra Suarez-Sharp, Ph.D., transitions to President, Regulatory Strategies Center of Excellence. Suarez-Sharp, who joined in 2020, brings a wealth of experience from the FDA and will focus on expanding the Center to meet growing biosimulation demands.
The company also announced the departure of:
- Brett Howell, Ph.D., President, Quantitative Systems Pharmacology, and
- Michael Raymer, President, Clinical Simulations & Medical Communications,
who will assist with the transition process.
O’Connor concluded, “We are grateful for Dr. Howell’s and Mr. Raymer’s contributions. Dr. Howell’s leadership has driven our QSP business forward, while Mr. Raymer played a crucial role in integrating Pro-ficiency. We wish them the best in their future endeavors.”
About Simulations Plus
With over 25 years of global experience, Simulations Plus is a leader in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, and commercialization. Our biosimulation solutions include AI/ML, pharmacokinetics, pharmacodynamics, and more. We provide simulation-enabled performance and intelligence solutions, along with medical communications support, to leading pharmaceutical, biotechnology, and regulatory agencies worldwide.
